• Explore /
  • Poster
  • / Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.

Abstract Video & Slides Poster

Authors

Marcia Cruz-Correa

Marcia Cruz-Correa

University of Puerto Rico, School of Medicine, San Juan, Puerto Rico

Marcia Cruz-Correa , Rui-Hua Xu , Markus H. Moehler , Do-Youn Oh , Ken Kato , David R. Spigel , Hendrik-Tobias Arkenau , Josep Tabernero , Anastasia V. Zimina , Yuxian Bai , Jianhua Shi , Keun-Wook Lee , Hidekazu Hirano , Lucjan S. Wyrwicz , Roberto Pazo Cid , Hui Xu , Tao Sheng , Gisoo Barnes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT03777657

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 290)

DOI

10.1200/JCO.2024.42.3_suppl.290

Abstract #

290

Poster Bd #

D10

Abstract Disclosures

Similar Posters

First Author: Hendrik-Tobias Arkenau

First Author: Samuel J Klempner

First Author: Elena Elimova

First Author: Eric Raymond